Table 2.

Recent and current clinical trials looking at direct or indirect targeting of autophagy. The clinical trials depicted will determine whether the selected inhibitors will improve clinical outcomes, which include increased sensitization of cancer cells to surgical intervention, chemotherapy, and other approved therapeutics.

CLINICAL TRIAL	PHASE	BREAST CANCER TYPE	INHIBITOR INVOLVED	DETAILS OF TRIAL	STATUS
NCT01292408	II	Anti-inflammatory invasive breast adenocarcinoma	Hydrochloroquine	Autophagy inhibitor between tumor biopsy and tumor excision	Recruitment status unknown
NCT01446016	II	Metastatic	Chloroquine plus taxane like chemotherapy	For patients that have failed anthracycline-based chemotherapy	Recruitment phase
NCT01023477	I/II	Ductal carcinoma in situ	Chloroquine	Inhibitor to decrease autophagy given before tumor excision	Recruitment phase
NCT02333890	II	Invasive breast cancer	Chloroquine	Inhibitor to decrease autophagy given before tumor excision and before chemotherapy treatment	Recruitment phase
NCT00063934	I/II	Metastatic and locally invasive breast cancer	Oblimersen plus chemotherapy	Bcl-2 inhibitor to increase apoptosis	Terminated
NCT02070094	I/II	HER2+	AT-737 plus T-DM1	Bcl-2 inhibitor to allow greater sensitivity to T-DM1 treatment	Withdrawn